nach oben

Breast Cancer Research

Erschienen in:

01.02.2010 | Editorial

Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?

verfasst von: Rodney J Scott

Erschienen in: Breast Cancer Research | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Genetic differences between individuals have been predicted to account for disparate outcomes in patients diagnosed with cancer. The search for genetic determinants has been ongoing for a considerable amount of time and it is only now that insights have been gained into which polymorphisms are most likely to be important in determining not only disease likelihood but also outcome. The quest to be able to accurately predict patient outcomes in breast cancer may now be a step closer as increased sample size is leading to more robust statistical analysis and a better understanding of molecular mechanisms of disease are forthcoming.

Schmidt Mk, Tommiska J, Broeks A, van Leeuwen FE, van't Veer LJ, Pharoah PDP, Easton DF, Shah M, Humphreys M, Dörk T, Reincke SA, Fagerholm R, Blomqvist C, Nevanlinna H: Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res. 2009, 11: R89-10.1186/bcr2460.CrossRefPubMedPubMedCentral

Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003, 33: 357-365. 10.1038/ng1093.CrossRefPubMed

Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang S-J, Strong LC, Lozano G, Levine AJ: A single nucleotide polypmorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004, 119: 591-602. 10.1016/j.cell.2004.11.022.CrossRefPubMed

Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ, De Vivo I: The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health study. Cancer Causes Control. 2007, 18: 621-625. 10.1007/s10552-007-9004-x.CrossRefPubMed

Campbell IG, Eccles DM, Choon DYH: No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. 2006, 240: 195-197. 10.1016/j.canlet.2005.09.003.CrossRefPubMed

Idbaih A, Boisselier B, Marie Y, Sanson M, Hallani SE, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Delattre J-Y: Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res. 2008, 1198: 16-20. 10.1016/j.brainres.2008.01.027.CrossRefPubMed

Alhopuro P, Ylisaukko-oja SK, Koskinen WJ, Bono P, Arola J, Järvinen HJ, Mecklin J-P, Atula T, Kontio R, Mäkitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen L-M, Asltonen LA: The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet. 2005, 42: 694-698. 10.1136/jmg.2005.031260.CrossRefPubMedPubMedCentral

Schmidt MK, reincke S, Broeks A, Braaf LM, Hogervorst FBL, Tollenaar RAEM, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PDP, Easton DF, Dörk T, Van't Veer LJ, on behalf of the Breast Cancer Association Consortium: Do MDM2 SNP309 and TP53R72P interact in breast cancer susceptibility? A large pooled seires from the breast cancer association consortium. Cancer Res. 2007, 67: 9584-9590. 10.1158/0008-5472.CAN-07-0738.CrossRefPubMed

Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T: Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2006, 43: 531-533. 10.1136/jmg.2005.037952.CrossRefPubMed

10.

Ruijs MWG, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, Verhoef S, van't Veer LJ: The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet. 2007, 15: 110-114. 10.1038/sj.ejhg.5201715.CrossRefPubMed

11.

Do TN, Ucisik-Akkaya E, davis CF, Morrison BA, Dorak MT: TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet. 2009, 195: 31-36. 10.1016/j.cancergencyto.2009.05.009.CrossRefPubMed

12.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn van de M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brwon PO, Botstein D, Lønning PE, Børresen-Dale A-L: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral

13.

Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EMJJ, Atkins D, Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365: 671-679.CrossRefPubMed

14.

Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, van't Veer LJ, Perou CM: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006, 355: 560-569. 10.1056/NEJMoa052933.CrossRefPubMed

Titel: Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
verfasst von: Rodney J Scott
Publikationsdatum: 01.02.2010
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 1/2010
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2474

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Effect of training-sample size and classification difficulty on the accuracy of genomic predictors

Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer

Risk of breast cancer among daughters of mothers with diabetes: a population-based cohort study

Familial relative risks for breast cancer by pathological subtype: a population-based cohort study

Tracking the genomic evolution of breast cancer metastasis

Promotion of variant human mammary epithelial cell outgrowth by ionizing radiation: an agent-based model supported by in vitro studies

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie